Seliciclib Withdrawn Phase 1 Trials for Cancer, Breast Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01333423Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)